Radiopharm Theranostics Ltd

Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic applications across oncology and neurology indications. The company's pipeline encompasses paired diagnostic and therapeutic candidates targeting high unmet medical needs in areas including brain metastases, HER-2 positive breast cancer, PD-L1 expressing non-small cell lung cancer, pancreatic cancer, prostate cancer, and glioblastoma. Product candidates utilize multiple technological approaches, including pivalate-based small molecules, monoclonal antibody nanoparticles (Nano-mAbs), and integrin-targeting compounds.

The company operates under a strategic collaboration with Lantheus Holdings, Inc., which provides support for advancing clinical development of its radiopharmaceutical candidates. This partnership arrangement represents a key element of the company's go-to-market strategy for advancing its pipeline.

Radiopharm Theranostics was incorporated in 2021 and maintains its headquarters in Carlton, Victoria, Australia. The company currently operates with 14 full-time employees and is listed on Nasdaq. As a pre-commercial clinical-stage entity, the company does not generate revenue from product sales and operates primarily through research and development activities and capital financing.